Here are six insights:
1. The investigated matters date back to between 2011 and 2013.
2. Orthofix voluntarily reported the accounting errors, launched an independent review and cooperated with the SEC. To avoid the problem in the future, Orthofix implemented structural initiatives and granular internal controls and process changes.
3. The second resolution involves an anti-bribery issue with Orthofix’s Brazilian subsidiary. Orthofix self-reported the incident to the Department of Justice and SEC, conducted an internal review with outside help and cooperated with the agencies during investigation. In response to this matter, Orthofix fired some employees and ended relationships with some third-party distributorships. Read more about how Orthofix responded here.
4. The company noted the resolutions reflect the same material terms it previously disclosed.
5. Orthofix accrued all monetary payments made to the SEC in the second and third quarters of 2016, funded into escrow in the fourth quarter of 2016.
6. Orthofix President and CEO Brad Mason commented, “We have instituted broad remedial measures designed to detect and prevent the issues that led to the matters being resolved…” in regards to the resolutions.
More articles on devices:
Zimmer Biomet names new President, Americas: Robert Delp — 5 key notes
Global biomaterials market to grow at 16% CAGR through 2021: 7 observations
VEXIM records $5.6M in Q4 2016 sales; gains momentum in spine trauma market — 8 highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
